MedPath
Found 11 clinical trials|View Analysis
Sort by:

The Efficacy and Safety of Lamotrigine Versus Carbamazepine in Focal Epilepsy

Phase 4
Conditions
Focal Epilepsy
Interventions
Drug: Lamotrigine tablet
Drug: Carbamazepine-Containing Product in Oral Dose Form
First Posted Date
2023-02-28
Last Posted Date
2023-10-10
Lead Sponsor
Dhaka Medical College
Target Recruit Count
70
Registration Number
NCT05748236
Locations
🇧🇩

Dhaka medical college, Dhaka, Bangladesh

Precision Medicine in the Treatment of Epilepsy

First Posted Date
2022-07-11
Last Posted Date
2024-04-11
Lead Sponsor
Gitte Moos Knudsen
Target Recruit Count
550
Registration Number
NCT05450822
Locations
🇩🇰

Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark

Comparative Bioavailability Study of Lamotrigine ER Tablets USP 50 mg

Phase 1
Completed
Conditions
Bioequivalence
Interventions
First Posted Date
2021-12-06
Last Posted Date
2021-12-07
Lead Sponsor
Alembic Pharmaceuticals Ltd.
Target Recruit Count
22
Registration Number
NCT05145608
Locations
🇨🇦

Algorithme Pharma, Mount Royal, Quebec, Canada

MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias

Phase 3
Recruiting
Conditions
Non-Dystrophic Myotonia
Interventions
First Posted Date
2021-08-23
Last Posted Date
2022-11-02
Lead Sponsor
University College, London
Target Recruit Count
60
Registration Number
NCT05017155
Locations
🇬🇧

University College London Hospital, London, United Kingdom

Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tablet Under Fasting Conditions

Phase 1
Completed
Conditions
Bioequivalence
Interventions
First Posted Date
2021-06-24
Last Posted Date
2022-09-08
Lead Sponsor
University of Karachi
Target Recruit Count
26
Registration Number
NCT04938856
Locations
🇵🇰

Center for Bioequivalence Studies and clinical research, Karachi, Sindh, Pakistan

The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mg

First Posted Date
2014-02-17
Last Posted Date
2017-05-10
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
138
Registration Number
NCT02064465
Locations
🇨🇳

GSK Investigational Site, Shanghai, China

The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects

First Posted Date
2013-06-17
Last Posted Date
2017-06-01
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
24
Registration Number
NCT01879423
Locations
🇨🇳

GSK Investigational Site, Shanghai, China

Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2009-02-03
Last Posted Date
2024-08-19
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
32
Registration Number
NCT00834561
Locations
🇨🇦

Anapharm Inc., Sainte-Foy, Quebec, Canada

Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2009-02-03
Last Posted Date
2024-08-19
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
32
Registration Number
NCT00835263
Locations
🇨🇦

Anapharm Inc., Sainte-Foy, Quebec, Canada

Lamotrigine for Symptoms of Geriatric Bipolar Depression

Phase 3
Completed
Conditions
Bipolar Disorder
Depression, Bipolar
Interventions
First Posted Date
2008-02-22
Last Posted Date
2014-12-30
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
57
Registration Number
NCT00621842
Locations
🇺🇸

University Hospitals Case Medical Center/ Case Western Reserve University, Cleveland, Ohio, United States

🇺🇸

Baylor College of Medicine/Michael E. DeBakey VAMC, Houston, Texas, United States

🇺🇸

Weill Medical College of Cornell University, White Plains, New York, United States

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath